Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2024Cancer MedicineOpen Access

A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study

View Full Paper
Ask AI
Bookmark
Share

Authors

FGFatih GürlerGazi UniversityFTFatih TayAli Osman Sonmez Oncology HospitalZİZehra Sucuoğlu İşleyenBezmiâlem Vakıf Üniversitesi

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gürler et al. (2024) studied this question.

synapsesocial.com/papers/68e62387b6db6435875b5d25https://doi.org/10.1002/cam4.70002
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2024 · 26,246 citations
  2. 2Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer2012 · 5,592 citations
  3. 3A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma1996 · 1,956 citations
  4. 4Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer2021 · 1,875 citations
  5. 5Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer2017 · 48 citations